Ductular reaction (DR) is characterized by the proliferation of reactive bile ducts induced by liver injuries. DR is pathologically recognized as bile duct hyperplasia and is commonly observed in biliary disorders. It can also be identified in various liver disorders including nonalcoholic fatty liver disease. DR is associated with liver fibrosis and damage, and the extent of DR parallels to patient mortality. DR raises scientific interests because it is associated with transdifferentiation of liver cells and may play an important role in hepatic regeneration. The origin of active cells during DR can be cholangiocytes, hepatocytes, or hepatic progenitor cells, and associated signaling pathways could differ depending on the specific liver injury or animal models used in the study. Although further studies are needed to elucidate detailed mechanisms and the functional roles in liver diseases, DR can be a therapeutic target to inhibit liver fibrosis and to promote liver regeneration. This review summarizes previous studies of DR identified in patients and animal models as well as currently understood mechanisms of DR. (Hepatology 2019;69:420-430).
T he term ductular reaction (DR) is defined as "a reaction of ductular phenotype, possibly but not necessarily of ductular origin," according to nomenclature that Roskams et al. introduced.
(1) DR is histologically observed in liver specimens and pathologically recognized as bile duct proliferation or hyperplasia and is commonly identified in biliary disorders such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary atresia (BA). DR is not described, however, as ductular proliferation, because this phenomenon encompasses a reaction associated with other liver tissues or cells, such as stroma, inflammatory cells, and infiltrated cells in the liver including bone marrow-derived macrophages.
(1) DR is often associated not only with bile duct proliferation but also with other reactions in the liver, such as inflammatory cell infiltration in portal areas.
(2) Hepatic progenitor cells (HPCs) are activated in chronic liver injury, and the HPC niche that consists of macrophages, myofibroblasts, and matrix develops and is associated with liver fibrogenesis during liver injury. (3) Bile ductules are consistently accompanied by microvessels, and the number of ductules corresponds to the density of accompanying microvessels, indicating a close relationship between DR and microvessels as well as angiogenesis. (4) Therefore, even when DR is identified in various liver conditions as bile duct hyperplasia, the mechanisms, associated cells/tissues, and reactions in DR may differ depending on the pathology. Although this review summarizes currently understood mechanisms and pathways of DR that is identified histologically as bile duct hyperplasia, it should be noted that other liver cells, tissues, or niches are also involved in DR and could play a key role for the pathophysiology of liver diseases associated with DR.
Types of DR in Liver Diseases
DR is described as cholangiocyte or HPC proliferation depending on the pathology. However, there is inconsistency in the definition of DR in previous studies because identification methods for HPCs are not conclusively established. In DR studies, Epithelial Cell Adhesion Molecule (EpCAM) and Sex-Determining Region Y-Box 9 (SOX9) have often been proposed as HPC markers, and Cytokeratin-7 (CK7) or Cytokeratin-19 (CK19) have been used to identify cholangiocytes. Cholangiocytes, however, also express EpCAM and SOX9; hence, these markers cannot identify HPC proliferation exclusively. Sackett et al. have identified Forkhead Box L1 (Foxl1) as an HPC marker and demonstrated that the subpopulation of Foxl1+ HPCs is rare in normal livers but dramatically increased in disease conditions caused for example by 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. (5) Trophoblast Cell Surface Antigen 2 (TROP2) and Leucine Rich Repeat Containing G Protein-Coupled Receptor 5 (Lgr5) have also been identified as markers of HPCs that proliferate during DDC-induced liver injury. (6, 7) Other suggested markers for HPCs include OV6, A6, CD24, CD133, Neuro-Glia Antigen 2 (NGA2), and C-X-C Motif Chemokine Receptor 4 (CXCR4). (8) (9) (10) Fig. 1 shows suggested locations of cholangiocytes, HPCs, and hepatocytes as well as selected markers proposed to identify these cells during liver injury.
SelF-pRolIFeRatIoN oF CHolaNgIoCyteS
Cholangiocytes are heterogeneous in protein expression as well as proliferative functions between small and large cholangiocytes. (11) DR (elevated CK19+ cells) can be identified in the liver of rodents with bile duct ligation (BDL) as large but not small cholangiocytes proliferate during BDL-induced liver injury. (12) Acute carbon tetrachloride (CCl 4 ) administration damages large but not small cholangiocytes in rats, and small cholangiocytes de novo proliferate showing DR (expanded CK19+ cells) to compensate for the loss of large cholangiocyte mass in this model. (13) As both small and large cholangiocytes express CK7 and CK19, it is not feasible to distinguish two subsets of cholangiocytes histologically using these markers. Three-dimensional tracking of labeled cholangiocytes revealed that cholangiocytes were heterogeneous in proliferative capacity during thioacetamide (TAA)-induced liver injury in vivo; some of these proliferative cholangiocytes were not clustered but scattered in biliary tree. (14) It was not
defined whether these proliferative biliary cells were small or large cholangiocytes or HPCs.
BIle DUCt RegeNeRatIoN DRIVeN By HepatoCyteS
DR during biliary injury is driven not only by cholangiocyte self-proliferation but also hepatocyte transdifferentiation. (15) (16) (17) Michalopoulos et al. isolated hepatocytes from dipeptidyl peptidase (DPP) IV+ rats and transplanted them into DPPIV-rats to generate chimera livers in vivo. (18) In this model, 47.5% of cholangiocytes were DPPIV+ after cholangiocyte damage caused by BDL plus pretreatment with 4,4'-methylenedianiline, suggesting that hepatocytes transdifferentiate into cholangiocytes during severe biliary damage. (19) Another study also transplanted hepatocytes isolated from DPPIV+ rats into DPPIVrats and found that some regenerated cholangiocytes were CK19+ as well as DPPIV+ after BDL, suggesting that those cholangiocytes were hepatocyte-derived. (20) Biliary damage caused by BDL or DDC diet induced morphological changes as well as Osteopontin (OPN) and SOX9 expression in hepatocytes, leading to transdifferentiation into cholangiocytes. (21) Tarlow et al. transplanted purified fluorescently marked hepatocytes into mice to trace these cells in vivo. (22) In this model, hepatocyte-derived biliary cells were observed after 6-week DDC diet. This study demonstrates that hepatocytes transdifferentiate directly into biliary phenotypes in vivo, and gene expression profiles of hepatocyte-derived biliary cells analyzed by RNAseq are different from those of cholangiocytes. FontBurgada et al. identified hybrid hepatocytes at canal of Hering that expressed SOX9 as well as Hepatocyte Nuclear Factor 4 alpha (HNF4α). (23) These hybrid hepatocytes showed robust proliferation and contributed to hepatocyte regeneration during acute liver injury caused by CCl 4 , and they also transdifferentiated into cholangiocytes during cholestatic liver injury caused by 3-week DDC diet. These findings suggest that hybrid hepatocytes may be HPCs or at least plastic enough to differentiate into hepatocytes or cholangiocytes depending on the specific liver injury. It is not fully understood, however, whether hepatocytes and/or hybrid hepatocytes transdifferentiate into identical cholangiocytes or biliary-like cells with different gene expression profiles from cholangiocytes in all liver injuries. Although these previous studies indicate that hepatocytes transdifferentiate into biliary cells, further studies are required to prove if this transdifferentiation may occur in human diseases.
HepatoCyte RegeNeRatIoN DRIVeN By CHolaNgIoCyteS aND/oR HpCS
Studies using liver specimens from patients with cirrhosis have identified typical cholangiocytes that express CK19 and hepatocytes expressing Hepatocyte Paraffin 1, but have found that there are transitional cells between cholangiocytes and hepatocytes expressing different markers such as EpCAM and Neural Cell Adhesion Molecule (NCAM). In addition, the expression level of markers in these transitional cells varies depending on the maturation of liver formation. (24, 25) It is not fully elucidated to date whether cholangiocytes and/or HPCs can transdifferentiate into hepatocytes during liver regeneration. Specific lineage labeling of the biliary compartment has demonstrated that proliferative cells during liver injuries are from the biliary compartment, but these cells do not contribute to hepatocyte regeneration. (26) Other studies have shown that regenerated hepatocytes in chronic liver injury are neither cholangiocyte-nor stem cell-derived but a result of self-duplication of hepatocytes. (27, 28) Despite controversies, accumulating evidence suggests that the origin of regenerated hepatocytes depends on the selected animal models and experimental conditions. In certain conditions with severe hepatocyte damage, cholangiocytes can transdifferentiate into hepatocytes through HPCs. Lu et al. have demonstrated that induction of hepatocyte damage (>98% hepatocyte loss) by Ah-Cre-mediated deletion of Mouse Double Minute 2 (Mdm2), which causes p53-mediated senescence and apoptosis in hepatocytes, induces DR (increased numbers of panCK+ cells) and activation of HPCs with biliary origin in mice. (29) This study showed that transplantation of biliary HPCs into other mice with severe hepatocyte loss facilitated liver regeneration by differentiation into hepatocytes. Another study has demonstrated that cholangiocytes change their morphological phenotypes, proliferate, and express SOX-9b followed by transdifferentiation into hepatocytes by expressing hepatocyte-specific proteins during bacterial nitroreductase-mediated hepatocyte ablation in zebrafish. (30) Raven et al. induced liver damage by TAA, DDC diet, or methionine-and choline-deficient diet and also inhibited hepatocyte growth factor signaling and regeneration by AAV8-TBG-Cre-mediated β1-integrin ablation in mice. (31) In this model, DR (elevated CK19+ cells) was observed in β1-integrin-deleted mice, and cholangiocytes became invasive, showing atypical morphology. This study showed that regenerated hepatocytes after the recovery period were not hepatocyte-but rather cholangiocyte-derived. Hepatocytes regenerated from cholangiocytes were located adjacent to CK19+SOX9+ cells; the number of those biliary-originated hepatocytes decreased with distance from CK19+ cells. Lineage tracing studies have demonstrated that biliary cells (cholangiocytes and/or HPCs) do not contribute to liver regeneration during liver injury induced by partial hepatectomy (PHx) or CCl 4 , proliferate but do not transdifferentiate into hepatocytes during DDC diet-induced injury, and proliferate and transdifferentiate into hepatocytes during choline-deficient-ethionine-supplemented (CDE) diet. (32, 33) Although it is still not fully elucidated whether cholangiocytes transdifferentiate into hepatocytes directly or via HPCs, these findings suggest that cholangiocytes and/or HPCs transdifferentiate into hepatocytes to restore parenchymal functions in certain liver conditions. Fig. 2 summarizes types of DR. Table 1 shows selected previous studies for DR identified in patients with various liver diseases. As there are no gold standard methods to identify specific cholangiocytes or HPCs and the origin of these cells conclusively, types of DR in these studies are unknown.
DR in Liver Diseases

CHoleStatIC lIVeR DISeaSeS
DR is often observed in patients with cholestatic liver diseases such as PBC, PSC, and BA. Liver specimen from patients with PBC or PSC showed extensive DR (expanded CK19+, EpCAM+, and OV6+ (34) DR (expanded CK7+ cells) was also identified from liver sections of patients with BA. (35) 
alCoHolIC aND NoNalCoHolIC lIVeR DISeaSeS
Heavy alcohol consumption induces acute or chronic alcoholic liver disease (ALD) including liver steatosis, inflammation, and fibrosis. Alcoholic hepatitis (AH) is the severe condition of ALD characterized by severe liver inflammation and fibrosis. Liver specimen from patients with AH showed DR (elevated expression of CK7 or EpCAM) compared with normal livers; the expression levels of CK7 correlated with 90-day survival rates of the patients, indicating association between grades of DR and mortality. (36) Dubuquoy et al. have also identified DR (elevated CK7+ or CK19+ cells) in patients with AH and have found that proliferation of hepatocytes is not elevated, indicating cholangiocyte-or HPC-derived DR. (37) Nonalcoholic fatty liver disease (NAFLD) shows similar liver steatosis to ALD without alcohol consumption. NAFLD can progressively lead to nonalcoholic steatohepatitis (NASH). Liver specimen of patients with NASH showed DR (expanded keratin-expressed area).
(2) In addition, patients with NASH at higher stages of liver fibrosis showed higher grades of DR, indicating a correlation between DR and disease progression of NASH.
(2)
CHRoNIC VIRal HepatItIS
DR (elevated CK19+ cells) was observed in patients with hepatitis B virus (HBV )-or hepatitis C virus (HCV )-positive liver cirrhosis. (38) Increased numbers of HPCs were also observed in liver sections, suggesting an association between DR and liver cirrhosis caused by viral infection. (38) Prakoso et al. have identified DR (expanded CK7+ area) in patients with HCV recurrence compared with healthy individuals; patients with higher liver fibrosis stages show higher DR. (39) In another study, DR (CK7+ area) was observed in patients with HCV recurrence after liver transplantation, and patients with more severe liver conditions such as cirrhosis or cholestatic hepatitis showed higher DR compared with patients with slow progression of HCV recurrence. (40) 
HepatoCellUlaR CaRCINoMa
A study using 120 patients with HBV-related hepatocellular carcinoma (HCC) has demonstrated that patients with higher grades of DR (CK19+ area) at peritumoral regions show higher inflammation grades or liver fibrosis stages. (41) Another study using patients with PHx and postoperative HCC has shown that Proliferating Cell Nuclear Antigen labeling index of DR is correlated with inflammation grades and fibrosis stages. (42) Park et al. analyzed patterns of DR (CK7+ cells) in patients with HCC and demonstrated that high grades of DR were observed in noninvasive HCC, but low or no DR was identified in highly invasive HCC, suggesting the possible feature of DR as a tool to distinguish invasive and noninvasive HCC. (43) 
Association of DR With Liver Fibrosis and Senescence
Studies using human liver specimens demonstrate that DR is closely related to liver fibrosis caused by various factors including alcoholic or nonalcoholic (44) inhibition of cholangiocyte proliferation and activation by blocking signaling pathways such as the secretin/ secretin receptor axis attenuated liver fibrosis as well as HSC proliferation and fibrogenesis via decreased Transforming Growth Factor beta 1 signaling, indicating a close relationship between cholangiocyte activation and HSC fibrogenesis. (45) HSC activation is associated with HPC proliferation and liver regeneration via production of hepatocyte growth factor (HGF). (46, 47) Another study has demonstrated that IL-13 induces proliferation of cholangiocytes as well as activation and fibrogenesis in fibroblasts independently. (48) Inhibition of IL-13 attenuated liver fibrosis in vivo, showing the key role of IL-13 signaling in liver fibrosis. (49) These findings indicate that liver fibrosis often accompanies DR because of the close relationship between HSCs and biliary cells, and DR can occur not only in biliary disorders but also in various liver injuries regulated by cytokines such as IL-13. This implicates the importance of DR and its grade as a sign of liver conditions and fibrosis during liver injury.
Although transdifferentiation of cholangiocytes into hepatocytes is still controversial, hepatocyte senescence caused by Mdm2 deletion induced biliary transdifferentiation into hepatocytes, indicating association between cellular senescence and differentiation of biliary cells. (29) Ikeda et al. analyzed liver specimen from patients with HBV-or HCV-induced hepatitis and found that the expression levels of p21 in hepatocytes correlated to the degree of DR (CK7+ or CK19+ cells), showing an association between hepatocyte senescence and biliary proliferation. (50) Another study identified DR (CK7+ cells) in patients with hereditary hemochromatosis and showed the association of DR with hepatocyte senescence, portal inflammation, and fibrosis stages. (51) Alcohol consumption increases cellular senescence in hepatocytes, and it is associated with liver fibrosis via miR-34a expression.
(52) Clouston et al. have shown strong correlation between DR and HPC expansion as well as association between hepatocyte senescence and HPC proliferation in HCV-positive patients. (53) Although further studies are required, these studies suggest that cellular senescence in hepatocytes may drive DR and fibrogenesis by inducing biliary proliferation and/or transdifferentiation.
Pathways of DR-Associated Transdifferentiation
NotCH SIgNalINg
Decoy oligodeoxynucleotide inhibition of Recombination Signal Binding Protein for Immunoglobulin Kappa J Region (RBP-jκ), which is a downstream target of Notch receptors, attenuated DDC-induced liver fibrosis in mice, suggesting association between Notch signaling and liver fibrogenesis. (54) Lu et al. have demonstrated that overexpression of RBP-Jκ in isolated murine HPCs induces HPC proliferation and elevated expression of CK7 and CK19 in HPCs, and inhibition of Notch signaling by DAPT (indirect Notch signaling blocker) attenuates expression of those cytokeratin proteins in vitro. (55) BDL-induced DR (expanded OV6+ or CK19+ cells) showing colocalization of OV6/CK19 and SOX9/CK19 and expression levels of Notch receptors and their ligands were also elevated by BDL in rats. (56) DAPT treatments attenuated BDL-induced liver fibrosis in vivo, and sodium butyrate-induced HPC differentiation into biliary phenotypes was inhibited by DAPT using WB-F344 cell line. (56) AAV8-TBG-Cre-mediated overexpression of Notch1 in hepatocytes elevates expression of OPN and SOX9 in hepatocytes in vivo. (21) These findings suggest that Notch signaling is associated with transdifferentiation of HPCs and/or hepatocytes into biliary phenotypes leading to DR followed by liver fibrosis.
HIppo/yeS-aSSoCIateD pRoteIN SIgNalINg
High expression of Yes-Associated Protein (YAP), which is an effector of Hippo signaling, was observed in bile ducts of patients with BA compared with patients without BA. (57) Elevated YAP expression in bile ducts was also identified in patients with PSC and PBC; YAP -/-mice showed attenuated bile duct hyperplasia during BDL, indicating association between DR and Hippo/YAP signaling. (58) Yimlamai et al. have demonstrated that hepatocyte-specific YAP expression induces elevated expression of HPC and biliary markers including CK19, SOX9, and A6, and have also shown that Notch signaling is a functional target of YAP in vivo. (59) These findings suggest that Hippo/YAP signaling is associated with DR and hepatocyte transdifferentiation into cholangiocytes via activation of Notch signaling.
WNt/β-CateNIN SIgNalINg
DDC diet increases the number of A6+ cells in the mouse liver, and β-catenin is colocalized with A6. (60) It has also been shown that A6+ cell numbers are decreased during DDC diet in β-catenin knockout mice, indicating association of β-catenin with DR during biliary damage. (60) Wntless is a protein required for transportation and secretion of Wnt Notch or Wnt/β-catenin signaling using CDE diet as a hepatocyte regeneration model and DDC diet as a cholangiocyte regeneration model in mice. (64) In this model, Notch signaling was reduced and Wnt/β-catenin signaling was maintained, leading to hepatocyte regeneration during CDE diet, and Notch signaling was upregulated and Wnt/β-catenin signaling was downregulated, leading to cholangiocyte regeneration during DDC diet. The authors have also demonstrated that Wnt/β-catenin signaling drives cholangiocarcinoma growth. (65) It is not fully understood whether Wnt/β-catenin signaling is required for both or either hepatocyte and cholangiocyte regeneration. Further studies are needed to elucidate functional roles of Wnt/β-catenin signaling in various liver injuries.
HgF/C-Met SIgNalINg
Human recombinant HGF induced liver regeneration in rats with PHx. (66) Mx1-Cre-mediated HGF receptor c-Met deletion in the liver decreased DR (CK19+ cells) and cell proliferation in the liver during DDC diet. (46) Alb-Cre-mediated c-Met deletion in hepatocytes also decreased numbers of A6+ HPCs in the liver compared with control. (46) Treatments of hepatocytes with HGF induced hepatocyte transdifferentiation into biliary phenotypes in vitro. (67) Inhibition of phosphatidylinositol 3-kinase, a downstream target of HGF/c-Met signaling, inhibited this transdifferentiation from hepatocytes into cholangiocytes. (67) These findings suggest that HGF/c-Met signaling is associated with hepatocyte transdifferentiation into cholangiocytes.
tWeaK/FN14 patHWay
A study has shown that CDE diet induces elevated Fn14 expression in the liver and Fn14 is colocalized with panCK. (68) This study has also demonstrated that Fn14 knockout mice show less DR (A6+ or CK19+ cell counts) during CDE diet compared with wildtype, and treatments of TWEAK, which is an Fn14 ligand, induce proliferation of the HPC line, BMOL cells suggesting an association between TWEAK/ Fn14 pathway and DR. Administration of recombinant TWEAK induced DR (expanded panCK+ cells) in mice. (69) Lu et al. have demonstrated that Fn14 knockout mice show less DR (panCK+ cells) after severe hepatocyte damage caused by Ah-Cremediated deletion of Mdm2. (29) Administration of recombinant TWEAK induced panCK+ cell expansion in Mdm2-deleted mice. (29) Although it is unclear whether TWEAK/Fn14 pathway is required for transdifferentiation, these findings suggest that this pathway is associated with HPC and/or cholangiocyte proliferation leading to DR. Fig. 3 summarizes signaling pathways associated with transdifferentiation leading to DR.
Conclusions and Perspectives
Current studies have demonstrated that DR is identified in various liver diseases, and types and mechanisms of DR may differ depending on liver injuries or animal models. Studies of DR are confusing depending on experimental conditions because of the complexity of DR. DR plays a key role in pathogenesis of various liver diseases and is associated with disease conditions such as liver fibrosis stages and mortality. DR is also an important factor for liver regeneration during both hepatocyte and cholangiocyte damage.
DR and cholangiocyte activation/proliferation can be a target for therapies of liver diseases. For example, we have demonstrated that melatonin administration or complete dark environment for BDL rats or Mdr2 -/-mice decrease cholangiocyte proliferation and bile duct mass as well as liver fibrosis via activation of Melatonin Receptor 1 melatonin receptor in cholangiocytes. (70) (71) (72) It is still unclear, however, whether DR promotes liver fibrosis via elevated bile duct mass and cholangiocyte activation or protects the liver during injury by enhancing liver regeneration. 
